Reckitt Benckiser Group plc (OTCMKTS:RBGLY) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Reckitt Benckiser Group plc (OTCMKTS:RBGLY) have earned an average rating of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have given a hold rating, one has assigned a buy rating and three have issued a strong buy rating on the company.

A number of equities research analysts have recently commented on RBGLY shares. JPMorgan Chase & Co. cut Reckitt Benckiser Group from an “overweight” rating to a “neutral” rating in a research report on Thursday, August 29th. UBS Group upgraded Reckitt Benckiser Group to a “strong-buy” rating in a research report on Wednesday, September 18th. Barclays upgraded Reckitt Benckiser Group to a “strong-buy” rating in a research report on Friday, October 4th. Finally, Citigroup upgraded Reckitt Benckiser Group to a “strong-buy” rating in a research report on Tuesday, October 1st.

Reckitt Benckiser Group Trading Down 1.6 %

OTCMKTS RBGLY opened at $12.70 on Friday. Reckitt Benckiser Group has a fifty-two week low of $10.24 and a fifty-two week high of $15.03. The company has a current ratio of 0.69, a quick ratio of 0.47 and a debt-to-equity ratio of 0.97. The stock has a 50-day simple moving average of $11.98 and a two-hundred day simple moving average of $11.43.

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.